Although lung cancer incidence is declining and five-year survival rates are increasing, lung cancer remains the top cause of cancer mortality in the United States, causing nearly 2.5 times more deaths than colorectal cancer and pancreatic cancer, according to the 2025 Cancer Statistics report from the American Cancer Society. The American Cancer Society reported an annual decline of 2.2% in lung cancer incidence from 2012 to 2021, with the five-year survival rate for lung cancer increasing over the decades, rising from 15% in 1995-1997 to 27% in 2014-2020. ...
Lung Cancers Today
A new medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and more.
Advertisement
Dr. Liu discusses remaining questions, key considerations, and how the data might shape the field moving forward.
The approval is for the first-line treatment of advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions.
The ORR of the external control group was 3%, while it was 36.8% in those who received amivantamab for NSCLC.
Learn how sublobar resection showed "comparable oncologic outcomes and complication rates" as lobectomy per a recent review.
The FDA action date for its regulatory decision is anticipated during the third quarter of this year.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
Sunvozertinib is an irreversible EGFR inhibitor that targets a wide spectrum of EGFR mutations.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
Advertisement
Roundtable Discussions on Lung Cancer
Expert Interviews on Lung Cancer
Conference Coverage
Find the latest news and updates on lung cancer from the ESMO Congress 2024.
Find the latest updates on lung cancer treatment and research from the IASLC 2024 World Conference on Lung Cancer.
Find the latest updates on lung cancer treatment and research from the 2024 ASCO Annual Meeting.
Our editors detail the latest data and innovations in the lung cancer space presented at ATS 2024.
Our editors deliver in-depth coverage of NACLC 2023, a premier event offering the latest data on lung cancer advancements.
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.